Resumen

SAEZ-TORRES DE VICENTE, M  y  APOLO-CARVAJAL, FE. Tocilizumab in the treatment of diffuse systemic sclerosis. Report of clinical case. Rev. OFIL·ILAPHAR [online]. 2024, vol.34, n.1, pp.78-79.  Epub 28-Mar-2025. ISSN 1699-714X.  https://dx.doi.org/10.4321/s1699-714x2024000100015.

Systemic sclerosis (SS) is a systemic autoimmune disease characterized by the development of vascular and immunological alterations, together with an excessive synthesis of collagen in the extracellular matrix, which causes obliterative vasculopathy and cutaneous and visceral fibrosis. The available treatments have limited effectiveness, among which immunosuppressive drugs are the first line3. Off- label treatment with tocilizumab, a monoclonal antibody that inhibits interleukin 6 (IL-6), has recently been proposed. The case of a patient with SS undergoing treatment with tocilizumab is described, providing information on the effectiveness and safety of tocilizumab in SS.

Palabras clave : Systemic sclerosis; tocilizumab; IL-6.

        · resumen en Español     · texto en Español     · Español ( pdf )